The story was updated to include a comment from Life Technologies.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences late Monday announced that a board of the US Patents and Trademark Office has ruled against Life Technologies in a patent interference claim in which PacBio was named the senior party.

As a result of the decision, all patent claims by Life Tech involved in the case were canceled, PacBio said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.